TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07317934: A Phase III, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Subretinal Injection of LX102 in Participants With Neovascular Age-Related Macular Degeneration - The STELLAR Trial

Sponsor: Innostellar Biotherapeutics Co.,Ltd · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 388 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,031,696

Rescue Site Savings

+$7,260,176

Unlock Full NCT07317934 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07317934 Rescue Dossier →